[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336254-105":59,"doc-detail-336254-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","acod1-expression-in-cancer-cells-promotes-immune-evasion-through-the-generation-of-inhibitory-peptides","Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides","","Targeting programmed cell death protein 1 (PD-1) is central to immune checkpoint blockade (ICB), yet many cancers resist these therapies. This study shows that αPD-1-resistant cancer cells generate abundant itaconate (ITA) via increased aconitate decarboxylase (Acod1). Lowering Acod1 in resistant cells can sensitize tumors to αPD-1 treatment. Mechanistically, Acod1-high cancer cells suppress naïve CD8+ T cell proliferation through inhibitory factor secretion that is surprisingly independent of ITA, driven instead by the release of small inhibitory peptides. These findings support strategies to counter Acod1 activity to improve ICB responses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/acod1-expression-in-cancer-cells-promotes-immune-evasion-through-the-generation-of-inhibitory-peptides/336254/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/acod1-expression-in-cancer-cells-promotes-immune-evasion-through-the-generation-of-inhibitory-peptides/336254.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is PD-1 targeting important, and why is it insufficient for many cancers?","Question",{"text":112,"@type":113},"PD-1 targeting is a key component of immune checkpoint blockade therapy, but it is not effective across cancer types due to immunosuppressive factors in the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do the findings say about Acod1 and itaconate in αPD-1-resistant cancer cells?",{"text":117,"@type":113},"αPD-1-resistant cancer cells produce abundant itaconate through enhanced Acod1 activity, and Acod1 is shown to be important for resistance.",{"name":119,"@type":110,"acceptedAnswer":120},"How do Acod1-high cancer cells suppress naïve CD8+ T cell proliferation?",{"text":121,"@type":113},"Acod1-high cancer cells inhibit naïve CD8+ T cell proliferation through secretion of small inhibitory peptides, and this suppression is not dependent on itaconate (ITA) in the study’s mechanistic analysis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336254,1790170790,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cell Rep. Author manuscript; available in PMC 2024 May 13. |\n| --- | --- |\n\nPublished in final edited form as:  \nCell Rep. 2024 April 23; 43(4): 113984. doi:10.1016/j.celrep.2024.113984 .  \nAcod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides  \nJames H. Schofield 1 , Joseph Longo2 , Ryan D. Sheldon3 , Emma Albano 1 , Abigail E. Ellis3 , Mark A. Hawk 1 , Sean Murphy 1 , Loan Duong 1 , Sharif Rahmy 1 , Xin Lu 1 , Russell G. Jones2 , Zachary T. Schafer1,4,*  \n1 Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556, USA  \n2 Department of Metabolism and Nutritional Programming, Van Andel Institute, Grand Rapids, MI 49503, USA  \n3Mass Spectrometry Core, Van Andel Institute, Grand Rapids, MI 49503, USA  \n4Lead contact  \nSUMMARY  \nTargeting programmed cell death protein 1 (PD-1) is an important component of many immune checkpoint blockade (ICB) therapeutic approaches. However, ICB is not an efficacious strategy in a variety of cancer types, in part due to immunosuppressive metabolites in the tumor microenvironment. Here, we find that αPD-1-resistant cancer cells produce abundant itaconate (ITA) due to enhanced levels ofaconitate decarboxylase (Acod1) . Acod1 has an important role in the resistance to αPD-1, as decreasing Acod1 levels in αPD-1-resistant cancer cells can sensitize tumors to αPD-1 therapy. Mechanistically, cancer cells with high Acod1 inhibit the proliferation of naive CD8+ T cells through the secretion of inhibitory factors. Surprisingly, inhibition of CD8+ T cell proliferation is not dependent on the secretion ofITA but is instead a consequence of the release of small inhibitory peptides. Our study suggests that strategies to counter the activity of Acod1 in cancer cells may sensitize tumors to ICB therapy.  \nGraphical Abstract  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Correspondence: [zschafe1@nd.edu](zschafe1@nd.edu).  \nAUTHOR CONTRIBUTIONS  \nJ.H.S., J.L., R.D.S., E.A., A.E.E., and M.A.H. conducted experiments, analyzed data, and interpreted results. S.M., L.D., S.R., and  \nX.L. generated the PRs and PRp cell lines and assisted with isolation ofT cells from mice. J.L., R.D.S., A.E.E., and R.G.J. were responsible for MS-based analysis. X.L., R.G.J., and Z.T.S. provided funding and supervision for the project. J.H.S. and Z.T.S. were responsible for conception/design of the project and wrote the manuscript with feedback from all other authors. Z.T.S. was responsible for overall study supervision.  \nSUPPLEMENTAL INFORMATION  \nSupplemental information can be found online at [https://doi.org/10.1016/j.celrep.2024.113984](https://doi.org/10.1016/j.celrep.2024.113984) .  \nDECLARATION OF INTERESTS  \nR.G.J. is a scientific advisor for Agios Pharmaceuticals and Servier Pharmaceuticals and is a member of the scientific advisory board of ImmunoMet Therapeutics.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nSchofield et al. Page 2  \nIn brief  \n[Schofield et al. report](Schofield et al. report) that cancer cells upregulate Acod1 as a survival strategy in response to αPD-1 therapy. Acod1hi cancer cells secrete inhibitory peptides that block the activation of naive CD8+ T cells. Loss ofAcod1 resensitizes resistant tumors to αPD-1 ICB.  \nINTRODUCTION  \nThe exploitation of the immune system to target cancer using the immune checkpoint blockade (ICB) strategy has revolutionized cancer treatment in recent years.1-3 More specifically, antibodies targeting programmed cell death protein 1 (PD-1) can dampen the natural resistance of cytotoxic CD8+ T cells toward host cells and lead to increased recognition and destruction of cancerous cells.4 Use of this strategy has shown strong efficacy ","cbCaioergPPUASUs","https://ap.wps.com/l/cbCaioergPPUASUs","pdf",1724247,34,"English","# Summary\n## PD-1/ICB resistance and tumor microenvironment metabolites\n## Role of Acod1 and itaconate in resistant cancer cells\n## Mechanism: inhibition of naïve CD8+ T cells by inhibitory peptides\n## Implications for sensitizing tumors to ICB","[{\"question\":\"Why is PD-1 targeting important, and why is it insufficient for many cancers?\",\"answer\":\"PD-1 targeting is a key component of immune checkpoint blockade therapy, but it is not effective across cancer types due to immunosuppressive factors in the tumor microenvironment.\"},{\"question\":\"What do the findings say about Acod1 and itaconate in αPD-1-resistant cancer cells?\",\"answer\":\"αPD-1-resistant cancer cells produce abundant itaconate through enhanced Acod1 activity, and Acod1 is shown to be important for resistance.\"},{\"question\":\"How do Acod1-high cancer cells suppress naïve CD8+ T cell proliferation?\",\"answer\":\"Acod1-high cancer cells inhibit naïve CD8+ T cell proliferation through secretion of small inhibitory peptides, and this suppression is not dependent on itaconate (ITA) in the study’s mechanistic analysis.\"}]","Acod1 expression in cancer cells promotes immune evasion through the generation of inhibitory peptides | PDF",1790014266,86,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3350f9bb1969fb52189f606740d4b544.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/92f4f8a5eb581d494d8e256a007ee796.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5df4ad1f515e978df9b81da0264786bd.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbc836d0a5daa0b1f50e8a19376fb55f.webp",980,1268]